---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-021752"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:37:31.334086+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Frequency reports Q1 net loss $19.5M; cash $66.7M, debt prepaid; MS program on track for 2024

## Summary
- Net loss of $19.5M vs $23.4M in Q1 2022; R&D expenses $11.4M, G&A $9.2M.
- Cash, equivalents and marketable securities $66.7M at March 31, 2023; all outstanding loans prepaid in April.
- MS remyelination program on track for clinical start in H1 2024; novel NCEs show robust in vivo remyelination.
- Preclinical data show statistical improvements in MRI white matter volume and oligodendrocyte differentiation across species.
- Company exploring strategic options to create shareholder value; restructuring extends cash runway into 2025.

## SEC filing metadata
- accession: 0000950170-23-021752
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/0000950170-23-021752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/freq-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-021752
- JSON: https://secwatch.observer/filing/0000950170-23-021752.json
- Plain text: https://secwatch.observer/filing/0000950170-23-021752.txt

## Key facts
- Earnings Releases
  Korro Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $19.5 million.
  - Period: the quarter ended March 31, 2023
  - Net income: Net loss was $19.5 million
  - Result: reported results
  source text: On May 12, 2023, Frequency Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703647/000095017023021752/0000950170-23-021752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.